Thymosin-α1 for recurrent implantation failure in IVF/ICSI
Official title: Thymosin-α1 for Recurrent Implantation Failure Following Transfer of PGT-a Tested Embryo: A Randomized, Double-Blind, Placebo-Controlled Trial
Run by Fakih IVF Fertility Center · NCT07675980 · Data updated 2026-11-12
This trial tests Thymosin-α1 to see if it helps women with recurrent implantation failure during IVF/ICSI cycles.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 40 Years |
| Sex | Women only |
| Enrollment | 136 (estimated) |
| Sponsor | Fakih IVF Fertility Center Academic / other |
| Locations | 2 sites (Abu Dhabi and 1 other locations) |
| Status | Recruiting |
| Started | February 11, 2026 |
| Main results expected | February 2027 |
| Study ends | June 2027 |
| Registry record updated | November 10, 2026 |
| Trial ID | NCT07675980 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women 18-40 years with at least 2 prior failed transfers using euploid embryos and normal uterine imaging.
✕Probably not a fit
Patients with non-immune causes of failure, active infections, uncontrolled systemic disease, or those on systemic immunosuppression may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study evaluates whether adding Thymosin-α1 to standard IVF/ICSI treatment is safe and can improve implantation and pregnancy outcomes in women with unexplained recurrent implantation failure. The program includes Phase 2 and Phase 3 cohorts to assess immune-modulatory effects and clinical efficacy. Participants are women aged 18-40 with at least two prior failed embryo transfers using euploid embryos and normal uterine imaging, compared against a placebo. The focus is on managing immune-related factors that may hinder implantation and early pregnancy.
Why it matters
Potential benefit: If successful, Thymosin-α1 could improve implantation rates and pregnancy outcomes for women with unexplained RIF.
How similar studies have gone: Previous observations and trials in immune-modulation suggest potential benefits, but data in RIF are still emerging and not yet definitive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. -Women 18-40 years 2. -RIF- ≥2 failed embryo transfers with PGT-a tested euploid embryos 3. \- Normal parental karyotypes 4. \- Normal uterine cavity on imaging 5. \- Negative antiphospholipid panel 6. \- Thyroid and prolactin controlled within local reference standards Exclusion Criteria: 1. Identified/correctable non-immune cause of RPL (chromosomal, anatomic, endocrine) 2. \- Active malignancy 3. -Active infection 4. \- Uncontrolled systemic disease 5. \- Current systemic immunosuppression
Where it's running
-
Fakih IVF Fertility Centre LLC
Abu Dhabi, United Arab Emirates Recruiting -
First IVF Fertility Centre
Abu Dhabi, United Arab Emirates Recruiting
Study contacts
- Principal investigator: Dr. Michael Fakih, MD — Fakih IVF Abu Dhabi
- Study coordinator: Dr. Lamiya Mohiyiddeen, MD, FRCOG
- Email: lamiya.mohiyiddeen@fakihivf.com
- Phone: +971543676002
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
G-CSF to help women with unexplained recurrent miscarriages
This study tests whether recombinant G-CSF can help women with two or more unexplained miscarriages who are undergoing IVF with tested embryos.
-
Correlation between PLC zeta measurements and semen parameters in male infertility
This study tests whether levels of the sperm protein PLCζ in semen relate to standard semen quality measures in men facing infertility.
-
Vitamin D Level at Frozen Embryo Transfer and Pregnancy Outcomes
This study looks at whether a woman's vitamin D level on the day of frozen embryo transfer affects her chances of pregnancy and delivering a baby.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.